News of Note—GeoVax, Inovio, BiondVax and more

In this week's news of note, GeoVax named a new CEO. (Pixabay)

Here is some other vaccine news of note for the week:

> GeoVax announced that its president and CEO Robert McNally is retiring at the end of the month, and that industry veteran David Dodd will take the role effective Sept. 1. McNally will remain on the company's board. Release

> Inovio Pharmaceuticals kicked off a phase 1/2 study of a therapeutic HIV vaccine called Pennvax-GP. Release


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> Investigators have enrolled the first patient in a phase 3 trial of BiondVax's universal flu vaccine candidate. Release

> A study published in Pediatrics found that children of mothers who received a prenatal Tdap vaccination were not more likely to be born with autism. Washington Post article

Suggested Articles

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.